The NCPE recommends that talazoparib (Talzenna®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.

Chronic migraine: The NCPE recommends that fremanezumab (Ajovy®), for the prophylaxis of migraine in adult patients with chronic migraine who have failed three or more migraine-preventive treatments, be considered for reimbursement. *

Episodic migraine: The NCPE recommends that fremanezumab (Ajovy®), for the prophylaxis of migraine in adult patients with episodic migraine who have failed three or more migraine-preventive treatments, be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments. *

The NCPE recommends that atezolizumab (Tecentriq®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. 

The NCPE recommend that dabrafenib and trametinib be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

The NCPE recommend that apalutamide (Erleada®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments.*

The NCPE recommends that lanadelumab not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

The NCPE recommends that letermovir be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

The NCPE recommends that pembrolizumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

The NCPE recommends that durvalumab be considered for reimbursement if cost effectiveness can be improved relative to existing treatments.*

Given the ongoing Covid-19 outbreak , the NCPE Annual Symposium “Update on Pharmacoeconomics in the Irish Healthcare Setting” is being postponed until later this year.